Jakob Paur

Novel p53-dependent anticancer strategy by targeting iron signaling and BNIP3L-induced mitophagy

W. Berger, B. Keppler, K. Nowikovsky, 2015, Oncotarget.

Is fibroblast growth factor receptor 4 a suitable target of cancer therapy?

W. Berger, B. Grasl-Kraupp, M. Grusch, 2014, Current pharmaceutical design.

Fibroblast growth factor receptor 3 isoforms: Novel therapeutic targets for hepatocellular carcinoma?

T. Mohr, W. Berger, C. Maier, 2015, Hepatology.

Fibroblast growth factor receptor 4: a putative key driver for the aggressive phenotype of hepatocellular carcinoma.

C. Pirker, T. Mohr, W. Berger, 2014, Carcinogenesis.

Novel p 53-dependent anticancer strategy by targeting iron signaling and BNIP 3 L-induced mitophagy

W. Berger, B. Keppler, K. Nowikovsky, 2015 .

Interaction of FGF9 with FGFR3‐IIIb/IIIc, a putative driver of growth and aggressive behaviour of hepatocellular carcinoma

T. Mohr, W. Berger, B. Grasl-Kraupp, 2020, Liver international : official journal of the International Association for the Study of the Liver.

EMA commentary on the ICH guideline for testing for carcinogenicity of pharmaceuticals

J. W. van der Laan, M. Pasanen, S. Beken, 2023, British journal of clinical pharmacology.